Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

Akeso's cadonilimab has received approval as a first-line treatment for advanced cervical cancer in combination with chemotherapy, potentially with bevacizumab, based on Phase III COMPASSION-16 study results that demonstrated significant improvements in progression-free and overall survival, even in patients with PD-L1 negative tumors; the drug is now included in 16 clinical treatment guidelines across various oncology indications and is undergoing trials for other cancer types, though Akeso cautions that regulatory approvals and commercial success are not guaranteed.

Analysis

Akeso, Inc. (9926.HK) has achieved a significant regulatory advancement with the approval of cadonilimab for first-line advanced cervical cancer when used in combination with chemotherapy. This approval is substantiated by the Phase III COMPASSION-16 study, which demonstrated statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard therapies. Notably, the cadonilimab regimen showed efficacy benefits in patients with PD-L1 negative tumors (CPS <1), a cohort comprising 27.9% of the treatment group, addressing a critical unmet need for immune-based therapies in this patient population, with benefits observed across both PD-L1 positive and negative subgroups. This development expands cadonilimab's coverage to all stages of advanced cervical cancer. The drug's credibility is further reinforced by its inclusion in 16 authoritative clinical treatment guidelines across various oncology indications and its ongoing investigation in over 30 Phase II and III clinical trials for other cancer types, including gastric, lung, and liver cancer. While this approval and the drug's pipeline signal strong potential, as reflected by a strongly positive sentiment score (0.75) and a specific ticker sentiment of 0.8 for 9926.HK, Akeso's forward-looking statements highlight inherent regulatory and commercialization risks. Additionally, an external AI analysis referenced in the article suggests that Akeso (9926.HK) may not currently be among the top undervalued stocks, indicating a need for careful consideration of its valuation.

Key Decisions for Investors

• Investors should assess the potential for increased revenue for Akeso (9926.HK) following cadonilimab's expanded approval into first-line cervical cancer, given its demonstrated efficacy, particularly in difficult-to-treat PD-L1 negative patients.
• Monitor upcoming catalysts from Akeso's extensive pipeline, specifically the progress of over 30 ongoing Phase II and III trials for cadonilimab, as positive results could further de-risk the asset and enhance its commercial value.
• Consider the disclosed risks in Akeso's forward-looking statements and the external perspective on its valuation, such as the InvestingPro insight, to maintain a balanced view when evaluating the investment opportunity.